Circio Holding ASA: Requested Conversion of Convertible Bonds

25 Oct 2024 18:12 CEST

Reference is made to Circio Holding ASA's (the "Company") outstanding
convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under
the Investment Agreement entered into between Atlas and the Company in March
2023.

Atlas has, by a notice of conversion, requested conversion of convertible bonds
with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are
convertible into 4,166,666 new shares in the Company at a conversion price of
NOK 0.6.

The Company's share capital will accordingly be increased by NOK 2,499,999.60 by
the issuance of 4,166,666 new shares upon completion of the conversion by
registration of the share capital increase in the Norwegian Register of Business
Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company's
total share capital will be NOK 17,711,803.80 divided into 29,519,673 shares,
each with a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) expression platform for
genetic medicine. The proprietary circVec technology is based on a modular
genetic cassette design for efficient biogenesis of multifunctional circRNA from
DNA and viral vectors, which can be deployed in multiple disease settings,
including cell and gene -therapy and chronic diseases. The circVec platform has
demonstrated enhanced and more durable protein expression vs. classic mRNA
vector systems and has the potential to become the new gold-standard for DNA and
virus-based therapeutics in the future. The circRNA R&D activities are being
conducted by the wholly owned subsidiary Circio AB based at the Karolinska
Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

More information:
Access the news on Oslo Bors NewsWeb site